Company intelligence / Profile preview

Ambros Therapeutics

Irvine, California, United States

Ownership: Private
Development stage: Other

Overview

Neridronate has been approved and used in Italy for over 10 years with demonstrated safety and efficacy in two Phase 3 CRPS studies, having been used in more than 600,000 patients to date. The compound has also demonstrated lasting pain reduction along with improvements in other CRPS-related symptoms in clinical studies.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Abiogen Pharma S.p.A.

Beyond the preview

Go deeper on Ambros Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambros Therapeutics.

Explore the full profile